Moderna, though early in development, prepares its vaccine for market

On the heels of an initial, positive look at the data in September, Moderna announced Thursday afternoon more results from a small study showing patients given its vaccine expressed high enough antibody levels to protect against CMV, short for cytomegalovirus.